ARS Pharmaceuticals (SPRY) Capital Expenditures Growth (3y) (2023 - 2025)
ARS Pharmaceuticals (SPRY) Capital Expenditures Growth (3y) (2023 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - | - |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - | - |
| 10 | ARS Pharmaceuticals | 591.71 Mn | 390.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -470.86% |
| Jun 30, 2025 | 540.07% |
| Mar 31, 2025 | 63.03% |
| Dec 31, 2024 | 33.28% |
| Sep 30, 2024 | 44.22% |
| Jun 30, 2024 | -28.43% |
| Mar 31, 2024 | 33.35% |
| Dec 31, 2023 | -30.20% |
| Jun 30, 2023 | -181.89% |
| Mar 31, 2023 | 80.17% |